Navigation Links
D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
Date:6/8/2009

y. D-Pharm successfully completed extensive testing of DP-b99 in pre-clinical and then in Phase I and Phase II clinical studies. Both preclinical and clinical studies indicate a favorable efficacy and safety profile for DP-b99. In the recently completed Phase IIb trial in 150 ischemic stroke patients, DP-b99 increased by two-fold the percentage of patients that completely recovered from ischemic stroke. DP-b99 may be administered within a nine hour therapeutic window.

About Stroke

Every year approximately 780,000 Americans have a new or recurrent stroke. The second most common cause of death worldwide, stroke is also the leading cause of serious long-term disability; 15% to 30% of stroke survivors experience permanent disability. According to the American Heart Association, the estimated direct and indirect cost in 2009 of stroke in the US is

$68.9 billion. Only about 2 to 5% of acute stroke patients are eligible for treatment with tissue plasminogen activator (tPA), the only FDA approved drug treatment for acute stroke.

About D-Pharm Ltd.

D-Pharm (http://www.dpharm.com) is a clinical stage, biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich pipeline of patent protected proprietary products. D-Pharm's pipeline includes advanced clinical stage products DP-b99 for treatment of acute ischemic stroke patients and DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and prophylaxis of migraine. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are at an earlier developmental stage, for cancer.

    For further information please contact:

    Tami Horovitz, PhD.
    Tel: +972-8-9385100
    Fax: +972-8-9300795
    Email: '/>"/>
SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. D-Pharm Secures Funding From Israels Chief Scientists Office
2. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
3. Yongye Biotechnology International Receives License to Manufacture Products
4. EarlySenses EverOn(TM) System Receives FDA Clearance and CE Mark Certification
5. Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners
6. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
7. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
8. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
9. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
10. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
11. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... CO / Rootstown, OH (PRWEB) January 22, 2015 ... detection platform, announced today that it has received AOAC-PTM Certifications ... O45, O1O3, O111, O121, and O145; collectively referred to as ... coli) O157, at 1 colony forming unit (cfu) per 325 ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... BASEL, Switzerland, March 26 Roche (SWX: ROG.VX; RO.S, ... Investments USA Inc., completed its tender offer for the ... ). The offer expired at midnight, New York City ... total of approximately 395.7 million shares of Genentech common ...
... Hello, , The investor ... has,been webcasted. The presentation is available in English from ... , a2e0f120f7f05e9c&portal_id=55a3fb63ef049550bc3b4d09baf7bf5e , (Due ... necessary to copy and paste,this hyperlink into your Internet ...
... BROOMFIELD, Colo., March 25 Accera, Inc., a biotechnology ... disorders, today announced that the company will be participating ... Founder, President and CEO, will speak at the 2nd ... a.m. EDT at the Sheraton Boston Hotel in Boston, ...
Cached Biology Technology:Roche Completes Tender Offer for Genentech 2Roche Completes Tender Offer for Genentech 3Accera, Inc. to Present at Upcoming Investor Conferences 2
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... offering. One major trend emerging in ... Multimodal biometric systems utilize more than one characteristic of ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... its School of Medicine. Funding for this $50 million capital ... be publicly launched next summer. The medical ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in Wake ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... PHILADELPHIA Results of a new study confirm trends ... certain cancers and worse cancer outcomes if they live in ... their homelands. "Hispanics are not all the same ... M.D., Ph.D., M.Sc., researcher in the Department of Epidemiology at ...
... breast or ovarian cancer are choosing to undergo surgery as ... a report in Cancer Epidemiology, Biomarkers & Prevention , ... "Women have their breasts or ovaries removed based on their ... a genetic test result and can take more than seven ...
... Most people who carry a genetic mutation for a ... phenomenon that has puzzled scientists since the first genetic ... The Feinstein Institute for Medical Research have figured out ... the disorder they have an additional lesion that ...
Cached Biology News:Moving to the US increases cancer risk for Hispanics 2Moving to the US increases cancer risk for Hispanics 3Women often opt to surgically remove their breasts, ovaries to reduce cancer risk 2Women often opt to surgically remove their breasts, ovaries to reduce cancer risk 3Abnormal brain circuits may prevent movement disorder 2
Polyclonal Antibody to AHI1 / Jouberin...
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Biology Products: